Stage 3 prostate cancer means that the cancer has spread outside the prostate gland into tubes that carry semen (seminal vesicles), bladder, pelvic wall, and the rectum. The stage of the cancer indicates how far it has spread and its overall size. Stages are used to help doctors come up with an informed choice for treatment.

Stage III prostate cancer is characterized by high levels of PSA with a fast growth rate of tumors. This is an indication that locally advanced cancer is very likely to grow and spread. Additional tests are administered if the PSA levels and Gleason's score are high [

It can be complicated, even for experienced doors, to figure out the stage of prostate cancer. It is believed that 95% of men (or 95 out of every 100 patients) will survive stage 3 prostate cancer for five years or more after the initial diagnosis [

What are the subtypes of stage 3 Prostate Cancer?

Stage 3 prostate cancer is further classified into subtypes IIIA, IIB, and IIIC. As a rule, an earlier letter indicates a lower stage. While every person’s prostate cancer experience is unique, most cancers have similar stages with a similar outlook that can receive the same treatment. Here are the stages of prostate cancer: 

IIIA: The cancer has not spread to nearby lymph nodes outside the prostate. It can be detected by a digital rectal exam or with imaging tests such as transrectal ultrasound. The grade group is 1 to 4, with a PSA level of at least 20. 

IIIB: The tumor has spread outside the prostate and may have also reached the seminal vesicles. It could have spread to nearby tissues such as the rectum, bladder, urethral sphincter, and the wall of the pelvis. However, at this stage, the cancer has not spread to nearby lymph nodes or elsewhere in the body. 

IIIC: The cancer may or may not grow outside the prostate and into nearby tissues. It hasn’t spread to nearby lymph nodes or elsewhere in the body. The cancer cells appear to look notably different compared to healthier cells. 

Stage 3 Prostate Cancer staging and diagnosis

 is used to describe and classify cancers, including Prostate Cancer, where:

The American Joint Committee on Cancer combines PSA levels and Gleason scores to identify the grade of prostate cancer. PSA stands for prostate-specific antigen, a protein produced by the prostate. High levels of PSA are often indicative of prostate cancer and are measured in ng/mL. 

A Gleason score helps doctors learn about the aggressiveness of the cancer. Each grade is a number between 1 and 5. Both scores are combined to provide a final score.

Prostate cancer is one of the most common types of cancer in the US, with 288,300 new cases registered in 2023 alone. Nearly 34.700 deaths are attributed to complications from prostate cancer. Prostate cancer is so prevalent that approximately 13 in every 100 American men will be diagnosed with the condition in their lifetime, with 2 in 3 men dying from complications [

How is stage 3 Prostate Cancer diagnosed?

Stage 3 prostate cancer is diagnosed by a procedure known as a biopsy. It's when doctors remove a small piece of tissue sample from the prostate and examine it under a microscope to see if there are any cancer cells. 	

The cancer cells are then given a grading based on their Gleason score. The score indicates how likely the cancer is to spread. 

There are a few types of biopsies that may be used to further study prostate cancer, including a transrectal biopsy and a transperineal biopsy. A transrectal biopsy is an ultrasound probe that is inserted into the rectum. It allows doctors to see where to pass the needle to collect tissue samples from the prostate.

A transperineal biopsy is when a needle is passed through the perineal skin and into the prostate instead of passing the needle through the rectum. The biopsy needle may be guided by an ultrasound inserted inside the rectum.

Although biopsies are shown to be reliable, they may still have problems such as:

Further tests of stage 3 prostate cancer may be conducted using MRI scans, PET scans, and CT scans to build a detailed picture of the body. Doctors may also conduct an isotope bone scan to see if the cancer has spread to the bones. 	

Stage 3 prostate can cause the following symptoms in patients:

Nearly all men with stage 3 cancer may experience erectile dysfunction. However, treatment can result in substantial improvement as long as the nerves are still intact. 

Patients with prostate cancer may undergo several types of treatment, including chemotherapy, immunotherapy, surgery, and biphosphate therapy. Treatments are available for bone pain caused by bone metastasis. New types of treatments are also being studied in clinical trials, such as photodynamic therapy, proton beam radiation therapy, and high-intensity focused ultrasound therapy, among others. 

Stage 3 Prostate Cancer primary/first-line treatment

The most common treatment options include external beam radiation therapy (EBRET) in combination with surgical removal of cancer, active surveillance without immediate treatment, and hormone therapy. In most cases, surgery on its own is not enough to treat prostate cancer. First-line treatment for stage 3 prostate cancer consists of EBRT with long-term androgen deprivation therapy. 

This treatment has been shown to improve the outcomes of many stage III patients [

Other types of treatment for stage 3 Prostate Cancer 

This section explores other types of treatment for stage 3 prostate cancer, including:

Stage 3 prostate cancer is curable because treatment can slow the growth of tumors. Moreover, there are several treatments that can extend the patient’s lifespan and reduce the signs and symptoms of prostate cancer. In some cases, if the cancer has spread, the aim is no longer to cure it but to improve the patient's quality of life and manage their symptoms. 

It is important to detect and treat stage 3 prostate cancer at an early stage. The vast majority of prostate cancer cases can be treated because tumors in the early stages are more likely to respond to treatment [

Prognosis: Stage 3 Prostate Cancer survival rate

The survival rate for stage 3 prostate cancer is predicated on how early it is detected and treated. Around 95% of men (or 95 out of 100) will survive the cancer for five years or more after diagnosis [

Moreover, the discovery of new treatment methods from clinical trials is showing promising results for patients with stage 3 prostate cancer. There is an 80 percent survival rate for cT3 diagnosis at 20 years compared to 099% for cT2 [

Although stage 3 prostate cancer can be cured, there is a high likelihood of recurrence. Studies show that about 20 to 30 percent of men will have a relapse after five years of initial therapy. The likelihood of recurrence depends on the aggressiveness of the cancer. Many online tools have been used to predict the likelihood of recurrence [

You can enter your values of PSA, Gleason score, and clinical stage in various online calculators to learn about your cancer recurrence rate. The Han Tables by Hopkins Medicine is a good online tool that gives you a good idea [

Although not all prostate cancers are alike, most instances of stage 3 prostate cancer are characterized by a slow growth rate. Prostate cancers use androgens as fuel for growth. This is why most prostate cancer treatments are involved around hormonal therapy to lower the patient’s androgen levels. 

Lifestyle changes for preventing and managing Prostate Cancer

Although there is no definitive protocol that patients can use to prevent prostate cancer, there are several lifestyle changes that can be made to reduce the risk of developing stage 3 prostate cancer and managing its symptoms. 

Stage 3 prostate cancer means that the cancer has spread from the prostate gland into tubes that carry semen. The survival rate for stage 3 prostate cancer is about 95%, and the patient's quality of life can be significantly improved by early treatment and making certain lifestyle changes, such as avoiding smoking and drinking, as well as being sexually active.

Stage 3 Prostate Cancer

Other Trials to Consider

Enzalutamide

Darolutamide

Sterotactic Body Radiotherapy

Cisplatin

Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy)

Enzalutamide

Olaparib

SUPR-SABR treatment

BMS-986460

IMP1734

Popular Categories

Prostate Cancer Clinical Trials 2024

Prostate Cancer Clinical Trials in Boston, MA

Prostate Cancer Clinical Trials in New York, NY

Prostate Cancer Clinical Trials in Ventura, CA

Prostate Cancer Clinical Trials in Glendale, AZ

Prostate Cancer Clinical Trials in Chicago, IL

Prostate Cancer Clinical Trials in Philadelphia, PA

Prostate Cancer Clinical Trials in Phoenix, AZ

Lymphedema Clinical Trials in Raleigh, NC

Recurrent Prostate Cancer Clinical Trials 2024

Popular Guides

Learn More About These Treatments

Kurvelo

Kionex

Minirin

Maxaquin

Limbitrol Ds

Lonsurf

Ticagrelor

Cefixime

Bortezomib

Marinol